1. AbdEl-Haq M, Kumar A, Ait Mohand FE, Kravchenko-Balasha N, Rottenberg Y, Domb AJ. Paclitaxel delivery to the brain for glioblastoma treatment. Int J Mol Sci 2023; 24: 11722.
2.
Adick A, Hoheisel W, Schneid S, Mulac D, Azhdari S, Langer K. Challenges of nanoparticle albumin bound (nab™) technology: comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension. Eur J Pharm Biopharm 2023; 193: 129-143.
3.
Ahlawat J, Guillama Barroso G, Masoudi Asil S, Alvarado M, Armendariz I, Bernal J, Carabaza X, Chavez S, Cruz P, Escalante V, Estorga S, Fernandez D, Lozano C, Marrufo M, Ahmad N, Negrete S, Olvera K, Parada X, Portillo B, Ramirez A, Ramos R, Rodriguez V, Rojas P, Romero J, Suarez D, Urueta G, Viel S, Narayan M. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. ACS Omega 2020; 5: 12583-12595.
4.
Babadi D, Dadashzadeh S, Osouli M, Abbasian Z, Daryabari MS, Sadrai S, Haeri A. Biopharmaceutical and pharmacokinetic aspects of nanocarrier-mediated oral delivery of poorly soluble drugs. Biopharmaceutical and pharmacokinetic aspects of nanocarrier-mediated oral delivery of poorly soluble drugs. J Drug Deliv Sci Technol 2021; 62: 102324.
5.
Banstola A, Duwa R, Emami F, Jeong JH, Yook S. Enhanced caspase-mediated abrogation of autophagy by temozolomide-loaded and panitumumab-conjugated poly(lactic-co-glycolic acid) nanoparticles in epidermal growth factor receptor overexpressing glioblastoma cells. Mol Pharm 2020; 17: 4386-4400.
6.
Bausart M, Préat V, Malfanti A. Combination for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 2022; 41: 35.
7.
Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanomed Nanotechnol Biol Med 2008; 5: 135.
8.
Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O’Shaughnessy JA. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7: 850-856.
9.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537-592.
10.
Bouras T, Lisanti MP, Pestell RG. Caveolin in breast cancer. Cancer Biol Ther 2004; 3: 931-941.
11.
Carpentier A, Stupp R, Sonabend AM, Dufour H, Chinot O, Mathon B, Ducray F, Guyotat J, Baize N, Menei P, de Groot J, Weinberg JS, Liu BP, Guemas E, Desseaux C, Schmitt C, Bouchoux G, Canney M, Idbaih A. Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nat Commun 2024; 15: 1650.
12.
Chatterjee M, Ben-Josef E, Robb R, Vedaie M, Seum S, Thirumoorthy K, Palanichamy K, Harbrecht M, Chakravarti A, Williams TM. Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer Res 2017; 77: 5925-5937.
13.
Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin Cancer Res 2009; 15: 5569-5575.
14.
Chavda VP, Dyawanapelly S, Dawre S, Ferreira-Faria I, Bezbaruah R, Gogoi NR, Kolimi P, Dave DJ, Paiva-Santos AC, Vora LK. Lyotropic liquid crystalline phases: drug delivery and biomedical applications. Eur J Pharm Sci 2023; 647: 123546.
15.
Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S, Morasso C, Occhipinti E, Polito L, Prosperi D, Ronchi S, Verderio P. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approaches. Pharmacol Res 2010; 62: 150-165.
16.
Daniel P, Meehan B, Sabri S, Jamali F, Sarkaria JN, Choi D, Garnier D, Kitange G, Glennon KI, Paccard A, Karamchandani J, Riazalhosseini Y, Rak J, Abdulkarim B. Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. Neurooncol Adv 2022; 4: vdac076.
17.
Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006; 121: 159-176.
18.
Dang Y, Guan J. Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 2020; 1: 10-19.
19.
Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 2013; 19: 1567-1576.
20.
Escalona-Rayo O, Fuentes-Vázquez P, Jardon-Xicotencatl S, García-Tovar CG, Mendoza-Elvira S, Quintanar-Guerrero DJ. Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: optimization of formulation variables and in vitro anti-glioma assessment. J Drug Deliv Sci Technol 2019; 52: 488-499.
21.
Fareed M, Qazi M, Ahmed S, Awan S, Qazi A. Cytotoxic assessment of quinoline based derivatives on liver cancer cell line: Quinoline compounds and their cytotoxicity. Pak BioMed J 2018; 31: 1.
22.
Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002; 110: 1309-1318.
23.
Fernandes C, Costa A, Osório L, Lago RC, Linhares P, Carvalho B, Caeiro C. Current standards of care in glioblastoma therapy. Exon Publications 2017; 20: 197-241.
24.
Ferraris C, Cavalli R, Panciani PP, Battaglia L. Overcoming the blood–brain barrier: successes and challenges in developing nanoparticle-mediated drug delivery systems for the treatment of brain tumours. Int J Nanomedicine 2020; 15: 2999-3022.
25.
Foote MJ. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biodrugs 2007; 13: 345-357.
26.
Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012; 2: 260-269.
27.
Gandhi K, Barzegar-Fallah A, Banstola A, Rizwan SB, Reynolds JN. Ultrasound-mediated blood–brain barrier disruption for drug delivery: a systematic review of protocols, efficacy, and safety outcomes from preclinical and clinical studies. Pharmaceutics 2022; 14: 833.
28.
Gao H, Cao S, Yang Z, Zhang S, Zhang Q, Jiang X. Preparation, characterization and anti-glioma effects of docetaxel-incorporated albumin-lipid nanoparticles. J Biomed Nanotechnol 2015; 11: 2137-2147.
29.
Gao MR, Xu YF, Jiang J, Yu SH. Nanostructured metal chalcogenides: synthesis, modification, and applications in energy conversion and storage devices. Chem Soc Rev 2013; 42: 2986-3017.
30.
Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14: 4200-4205.
31.
George J, Banik NL, Ray SK. Molecular mechanisms of taxol for induction of cell death in glioblastomas. In: Ray S (Ed.). Glioblastoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0410-2_14
32.
Graham-Gurysh EG, Murthy AB, Moore KM, Hingtgen SD, Bachelder EM, Ainslie KM. Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy. J Control Release 2020; 323: 282-292.
33.
Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P, Hawkins MJ. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17: 1263-1268.
34.
Hau P, Fabel K, Baumgart U, Rümmele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hübner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004; 100: 1199-1207.
35.
Hohmann N, Sprick MR, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A, Springfeld C. Protocol of the IntenSify-Trial: an open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination’s pharmacokinetics, safety, and efficacy. Cancers (Basel) 2023; 16: 2483-2493.
36.
Huizing MT, Keung A, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. Clin Cancer Res 1993; 11: 2127-2135.
37.
Jamalpour S, Alinezhad A, Sabah JT, Vazifehmand R, Behrooz AB, Hamzah ASA, Al-Sadat Davazdahemami A, Monem Homaie F, Mahdokht Maddah S. Modulating Wnt/b-Catenin signaling pathway on U251 and T98G glioblastoma cell lines using a combination of paclitaxel and temozolomide: a molecular docking simulations and gene expression study. Mol Neurobiol 2023; 71: 766-774.
38.
Jeevanandam J, Chan YS, Danquah MK. Nano-formulations of drugs: recent developments, impact and challenges. Biotechnol Adv 2016; 128: 99-112.
39.
Jia L. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: approaches, experimental evidence and theory. Curr Nanosci 2005; 1: 237-243.
40.
Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget 2015; 6: 8788.
41.
Kim J, Ahn SI, Kim YJ. Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system. J Ind Chem Eng 2019; 73: 8-18.
42.
Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19: 899-909.
43.
Kuo YC, Rajesh R, Yen MH, Paira P. Inhibition of glioblastoma and macrophage phagocytosis using sialic acid-grafted tamoxifen-carmustine-polyethyleneimine-poly(lactic-co-glycolic acid) nanoparticles. Int J Chem Eng 2020; 111: 302-311.
44.
Kurdi M, Butt NS, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, et al. The impact of IDH1 mutation and MGMT promoter methylation on the recurrence-free interval in glioblastoma patients treated with radiotherapy and chemotherapeutic agents. Pathol Oncol Res 2021; 27: 1609778.
45.
Lei C, Davoodi P, Zhan W, Chow PKH, Wang CH. Development of nanoparticles for drug delivery to brain tumour: the effect of surface materials on penetration into brain tissue. J Pharm Sci 2019; 108: 1736-1745.
46.
Li J, Wang L, Sun Y, Wang Z, Qian Y, Duraisamy V, Al Antary TM. Zerumbone-induced reactive oxygen species-mediated oxidative stress re-sensitizes breast cancer cells to paclitaxel. Cancer Lett 2023; 70: 28-37.
47.
Liu Y, Hong G, Mao L, Su Z, Liu T, Liu HJ. A novel paclitaxel derivative for triple-negative breast cancer chemotherapy. Med Oncol 2023; 28: 3662.
48.
Liu Y, Li Y, Shen W, Li M, Wang W, Jin X. Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects. Front Pharmacol 2024; 15: 1409163.
49.
Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. Self-assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma. Adv Sci (Weinh) 2024; 30: e14528.
50.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumours of the central nervous system: a summary. Acta Neuropathol 2021; 23: 1231-1251.
51.
Lu J, Xu F, Rao C, Shen C, Jin J, Zhu Z, Wang C, Li Q. Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology. Front Pharmacol 2022; 13: 1076958.
52.
Madani F, Esnaashari SS, Webster TJ, Khosravani M, Adabi MJ. Polymeric nanoparticles for drug delivery in glioblastoma: state of the art and future perspectives. J Control Release 2022; 349: 649-661.
53.
McPheron MA, Felker MV. Clinical perspectives: treating spinal muscular atrophy. Mol Ther 2024; 32: 2489-2504.
54.
Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene 2009; 28: 3551-3562.
55.
Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol 2017; 8: 566-571.
56.
Mu Q, Wang L, Yu F, Gao H, Lei T, Li P, Liu P, Zheng X, Hu X, Chen Y, Jiang Z, Sayari AJ, Shen J, Huang H. Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cell Signal 2015; 16: 623-633.
57.
Nawara HM, Afify SM, Hassan G, Zahra MH, Seno A, Seno M. Paclitaxel-based chemotherapy targeting cancer stem cells from mono-to combination therapy. Biomed Pharmacother 2021; 9: 500.
58.
Norouzi M, Yathindranath V, Thliveris JA, Kopec BM, Siahaan TJ, Miller DW. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Sci Rep 2020; 10: 11292.
59.
Panday VR, Rosing H, Huizing MT, Koopman FJ, van Warmerdam LJ, ten Bokkel Huinink WW, Beijnen JH. Urinary excretion of paclitaxel and metabolites in a large series study. J Oncol Pharm Pract 1998; 4: 159-164.
60.
Pandit C, Roy A, Ghotekar S, Khusro A, Islam MN, Emran TB, Lam SE, Khandaker MU, Bradley DA. Biological agents for synthesis of nanoparticles and their applications. J King Saud Univ Sci 2022; 34: 101869.
61.
Pandita D, Kumar S, Lather V. Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives. Drug Discov Today 2015; 20: 95-104.
62.
Qu S, Huang C, Zhu T, Wang K, Zhang H, Wang L, Xu R, Zheng H, Yuan X, Liu G, Zhu R, Qu J, Yi G, Qi S. OLFML3, as a potential predictor of prognosis and therapeutic target for glioma, is closely related to immune cell infiltration. Cancer Biol Med 2023; 4: 20220052.
63.
Qu S, Qi S, Zhang H, Li Z, Wang K, Zhu T, Ye R, Zhang W, Huang G, Yi GZ. Albumin-bound paclitaxel augments temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. Cancer Lett 2023; 42: 285.
64.
Rahman M, Chan APK, Tang M, Tai IT. A peptide of SPARC interferes with the interaction between Caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One 2011; 6: e26390.
65.
Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol 2020; 11: 55-60.
66.
Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, López-Picazo JM, Sanmamed MF, Melero I. Paradigms on immunotherapy combinations with chemotherapy. Front Oncol 2021; 11: 1353-1367.
67.
Sati P, Sharma E, Dhyani P, Attri DC, Rana R, Kiyekbayeva L, Büsselberg D, Samuel SM, Sharifi-Rad J. Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. Pharmacol Res 2024; 29: 90.
68.
Shiroyama T, Tamiya M, Minami S, Takata S, Masuhiro K, Futami-Nishijima Y, Uenami T, Mori M, Koba T, Matsuki T, Takimoto T, Suzuki H, Okamoto N, Komuta K, Hirashima T, Kumanogoh A, Kijima T. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study. Lung Cancer 2017; 80: 461-467.
69.
Siddiqui MF, Sadiq E. Resistance and sensitivity: competitive mechanisms of cisplatin. Int J Pharm Sci Res 2015; 6: 3139-3145.
70.
Khanaposhtani M, Dastyafteh N, Gohari MR, Tehrani MM, Larijani B, Mahdavi M, Firuzi O. Design, synthesis, and cytotoxic activity of 2-amino-1, 4-naphthoquinone-benzamide derivatives as apoptosis inducers. Sci Rep 2024; 14: 27302.
71.
Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235: 179-192.
72.
Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, Gomez C, Bebawy JF, Liu BP, Bouchoux G, Desseaux C, Helenowski IB, Lukas RV, Dixit K, Kumthekar P, Arrieta VA, Lesniak MS, Carpentier A, Zhang H, Muzzio M, Canney M, Stupp R. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Nat Commun 2023; 24: 509-522.
73.
Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of albumin as a carrier in nano-drug delivery. Mol Pharm 2021; 18: 1862-1894.
74.
Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA. Temozolomide and other alkylating agents in glioblastoma therapy. Clin Transl Neurosci 2019; 7: 69.
75.
Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. The Breast 2021; 55: 63-68.
76.
Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Cancers (Basel) 2022; 12: 4734.
77.
Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. J Transl Neurosci 2015; 3: 152-169.
78.
Vishwanath K, Wilson B, Geetha KM, Murugan V. Polysorbate 80-coated albumin nanoparticles to deliver paclitaxel into the brain to treat glioma. Ther Deliv 2023; 14: 193-206.
79.
Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19: 142-149.
80.
Wong W, Sun P, Mu Z, Liu J, Yu C, Liu A. Efficacy and safety of nab-paclitaxel as second-line chemotherapy for locally advanced and metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 2017; 37: 4687-4691.
81.
Xu H, Zhang Y, Li L, Ren Y, Qian F, Wang L, Ma H, Quan A, Liu H, Yu R. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. Adv Sci (Weinh) 2023; 30: 1-13.
82.
Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumours. Jpn J Clin Oncol 2010; 40: 404-411.
83.
Yasuda Y, Hattori Y, Tohnai R, Ito S, Kawa Y, Kono Y, Urata Y, Nogami M, Takenaka D, Negoro S, Satouchi M. The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 2018; 48: 89-93.
84.
Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, Sakamori Y, Nagai H, Handa T, Kubo T, Kim YH. Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Ther Clin Risk Manag 2017; 7: 677-680.
85.
Yu HT, Meng D, Feng MX, Ruan KY, Dong JJ, Xiao YP, Zhang XH, Shi LL, Jiang XH. RGD-modified solid lipid nanoparticles improve oral doxorubicin absorption: In vitro and in vivo study. J Drug Deliv Sci Technol 2024; 91: 105293.
86.
Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008; 83: 761-769.
87.
Zhang X, Guo Q, Zhao Z, Cheng P, Wu A, Liu H. Engineering prodrug nanoparticles for targeted therapy in heterogeneous glioblastoma. Chem Eng J 2023; 474: 145557.
88.
Zhu AX, Rosmorduc O, Evans T, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2014; 23: ixe11.
89.
Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi R, Zhao F. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Oncol 2015; 35: 340-348.
